Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274533 | 0.83 | HCAR2 (0.58) | HCAR2ATMSMYD3HTTRAB9A | |
| SCHEMBL8237840 | 0.82 | HCAR2 (0.62) | HCAR2ATMSMYD3HTTRAB9A | |
| SCHEMBL9706109 | 0.78 | ACHE (0.60) | HCAR2ACHECES1MLYCD | |
| SCHEMBL29503159 | 0.78 | HCAR2 (0.67) | HCAR2ATMSMYD3HTTRAB9A | |
| SCHEMBL832732 | 0.78 | HCAR2 (0.67) | HCAR2ATMSMYD3HTTRAB9A | |
| SCHEMBL20186007 | 0.77 | TPMT (0.52) | ACHECES1MLYCD | |
| SCHEMBL23181527 | 0.77 | HCAR2 (0.41) | HCAR2ACHECES1MLYCD | |
| SCHEMBL16600044 | 0.77 | POLB (0.60) | HCAR2SMYD3HTTRAB9A | |
| SCHEMBL7974908 | 0.77 | HCAR2 (0.60) | HCAR2ACHESMYD3CES1 | |
| Hydrochloric Acid SCHEMBL9706116 | 0.77 | ACHE (0.58) | HCAR2ACHECES1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848610-B1 | Inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-3048099-A2 | INHIBITORS OF KINASE ACTIVITY | YM BioSciences Australia Pty Ltd (AU) | 2016-07-27 | — | — | EP | disclosed |
| US-9029386-B2 | Pyridine derivatives useful as kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2848610-A1 | Inhibitors of kinase activity | YM BioSciences Australia Pty Ltd (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-05-30 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| EP-2099774-A1 | INHIBITORS OF KINASE ACTIVITY | Cytopia Research Pty Ltd (AU) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008058341-A1 | INHIBITORS OF KINASE ACTIVITY | CYTOPIA RESEARCH PTY LTD (AU) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | HCAR2 1606/4885ATM 204/4885ACHE 2593/4885 |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | HCAR2 1606/4885ATM 204/4885ACHE 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.